Vistagen therapeutics

 Vistagen is committed to equal employment opportuni

Vistagen is committed to equal employment opportunity and providing reasonable accommodations to applicants with physical and/or mental disabilities. We value and encourage diversity and solicit applications from all qualified applicants without regard to race, color, gender, sex, age, religion, creed, national origin, sexual orientation ...Stay up-to-date on Vistagen Therapeutics, Inc. Common Stock (VTGN) news with the latest updates, breaking headlines, news articles, and more from around the ...

Did you know?

Sponsor: VistaGen Therapeutics, Inc. Information provided by (Responsible Party):. VistaGen Therapeutics, Inc. Study ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen’s six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful ...Based on 1 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $12.00 with a high ...Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080. Investor Relations Contact. Vistagen Therapeutics. Mark McPartland Senior Vice President, Investor Relations +1(650) 577-3606 [email protected]. Disclaimer.VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need.VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .SOUTH SAN FRANCISCO, Calif., April 01, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals ...Fasedienol, itruvone, and VistaGen’s other pherines (PH80, PH15, and PH284) address major markets across mental health crisis to women’s health. Price Action: VTGN shares are up 13.42% at $4. ...Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, …Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, …SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), … Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed mechanism of action (MOA) of fasedienol is novel and ... AV-101 VistaGen Therapeutics major depressive disorder (Fast Track), Phase II (NMDA receptor glycine B antagonist) South San Francisco, CA major depressive disorder …VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. ... Vistagen is developing an innovative pipeline of neuroscience medications with ...The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts.Based on 1 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $12.00 with a high ...About VistaGen Therapeutics. VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. Drug rescue involves the combination of human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants of once-promising small molecule …At Vistagen, corporate responsibility is fundamental to our mission and we are committed to holding ourselves to high ethical standards. Beyond our quest to pioneer new neuroscience therapies, we strive to create a positive impact for our employees, our local communities, our patients, our stockholders, the healthcare ecosystem, and society.At Vistagen, corporate responsibility is fundamental to our mission and we are committed to holding ourselves to high ethical standards. Beyond our quest to pioneer new neuroscience therapies, we strive to create a positive impact for our employees, our local communities, our patients, our stockholders, the healthcare ecosystem, and society.Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals …

Significant control over Vistagen Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders ...Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging ...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ...In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this p...SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Jun. 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today …

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year 2024 Second Quarter ...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopha. Possible cause: Vistagen’s pipeline includes six clinical-stage drug candidates, including its most.

2 days ago · Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Amount of Analyst Coverage. Vistagen Therapeutics has received no research coverage in the past 90 days. Read more about Vistagen Therapeutics' stock forecast and price ... Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders.

About us. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and …Vistagen is presently conducting an exploratory Phase 1B drug-drug interaction clinical study of AV-101 in combination with probenecid. The FDA has granted Fast Track designation for development of AV-101 as a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain. About Vistagen

A beaten down micro-cap biotech company, Vi VistaGen terapéutica, Inc. Volver a Subvenciones. Premios totales: 1. Valor del premio: $971,558. Tipo de institucion: Con fines de lucro. Nombre corto:. (1) execute for and on behalf of the undersigned, in the undersigned's3 days ago · Vistagen Therapeutics, In Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ...VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate … Vistagen Therapeutics, Inc. 343 Allerton Avenue South Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15 ... Vistagen Therapeutics had a negative return on equity of 72.1Senior Vice President, Translational Neuroscience. Dr. Monti joined VistaGen Therapeutics is a biopharmaceutical company committe Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety,... PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ... Vistagen Therapeutics, Inc., a late clinical-stage biopharmac Vistagen Therapeutics. VTGN. $4.76. +0.06 (+1.28%) Share Price. as of April 19 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. Vistagen Therapeutics (VTGN) Stock Key Data ... VistaGen Therapeutics, Inc. is a clinical-s[VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biophaSOUTH SAN FRANCISCO, Calif., October 02, 2023--Vistagen Therape Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression ... Vistagen Therapeutics, Inc. stock has split three times since the company went public. The most recent was a 333333-for-10000000 split on 06/07/2023. View VTGN's stock split history here .